NASDAQ: LYRALyra Therapeutics Inc Stock
$5.21+0.02 (+0.39%)
Updated Apr 22, 2024
LYRA Price
$5.21
Fair Value Price
-$1.55
Market Cap
$311.26M
52 Week Low
$1.93
52 Week High
$6.79
P/E
-4.13x
P/B
3.48x
P/S
167.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.56M
Earnings
-$62.68M
Gross Margin
100%
Operating Margin
-4,019.32%
Profit Margin
-4,023.1%
Debt to Equity
0.6
Operating Cash Flow
-$63M
Beta
0.5
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LYRA Overview
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LYRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LYRA ($5.21) is overvalued by 435.13% relative to our estimate of its Fair Value price of -$1.55 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LYRA ($5.21) is not significantly undervalued (435.13%) relative to our estimate of its Fair Value price of -$1.55 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LYRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LYRA due diligence checks available for Premium users.
Be the first to know about important LYRA news, forecast changes, insider trades & much more!
LYRA News
Valuation
LYRA fair value
Fair Value of LYRA stock based on Discounted Cash Flow (DCF)
Price
$5.21
Fair Value
-$1.55
Undervalued by
435.13%
LYRA ($5.21) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LYRA ($5.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LYRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LYRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.13x
Industry
16.21x
Market
41x
LYRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.48x
Industry
5.82x
LYRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LYRA's financial health
Profit margin
Revenue
$146.0k
Net Income
-$15.2M
Profit Margin
-10,380.8%
LYRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LYRA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$142.6M
Liabilities
$53.2M
Debt to equity
0.6
LYRA's short-term assets ($104.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LYRA's short-term assets ($104.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LYRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LYRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.1M
Investing
-$2.4M
Financing
$18.9M
LYRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LYRA vs Biotech Stocks
Lyra Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.